MAIA Biotech Hits Enrollment Goals in Two Lung Cancer Trials
MAIA Biotechnology has completed enrollment in one trial arm and reached 65% of its 2026 target in a pivotal Phase 3 study targeting non-small cell lung cancer.
MAIA Biotechnology announced back-to-back enrollment milestones in its ongoing clinical program targeting non-small cell lung cancer, signaling steady progress toward regulatory-stage data that could shape the company's near-term pipeline prospects.
The Chicago-based biotech confirmed that patient enrollment in Part C of the THIO-101 Phase 2 study is now complete, a benchmark that clears the way for the company to gather and analyze outcomes data from that cohort. Phase 2 studies are typically designed to assess efficacy signals and safety profiles before advancing to larger, confirmatory trials.
Read more Buchanan Capital, Vault Partners Close Houston Industrial JV Deal →
Separately, MAIA reported that its pivotal THIO-104 Phase 3 study has reached 65% of its full enrollment target for 2026. Pivotal trials carry particular regulatory weight because their results are generally submitted directly to health authorities such as the FDA as the primary basis for approval decisions. Reaching nearly two-thirds of the enrollment threshold suggests the company is on track to meet its stated timeline.
Both studies center on THIO, MAIA's investigational telomere-targeting agent, which the company is evaluating as a treatment for non-small cell lung cancer — the most common form of lung cancer and a leading cause of cancer mortality in the United States. The dual milestone announcement reflects the company's effort to advance its clinical program on parallel tracks, compressing the overall development timeline.
Continue reading at GlobeNewswire - Industry News on Financial Services.
